New Key Statistics Module, Z-Score and F-Score
NAS:DNTH Key Ratios
| Market Cap $ M | 5,868.64 |
| Enterprise Value $ M | 4,983.11 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 4.91 |
| Price/Sales | 2,623.02 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1.00 |
| EPS (TTM) $ | -4.15 |
| Beneish M-Score | 2.16 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -22.87 |
| EV-to-EBITDA | -22.91 |
| PEG | -- |
| Shares Outstanding M | 55.93 |
| Net Margin (%) | -10,096.95 |
| Operating Margin % | -11,441.39 |
| Pre-tax Margin (%) | -10,096.95 |
| Quick Ratio | 26.10 |
| Current Ratio | 26.10 |
| ROA % (ttm) | -24.68 |
| ROE % (ttm) | -25.87 |
| ROIC % (ttm) | -131.90 |
| Dividend Yield % | -- |
| Altman Z-Score | 85.96 |
DNTH Number of Guru Trades
DNTH Volume of Guru Trades
Gurus Latest Trades with NAS:DNTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:DNTH is held by these investors
Total 2
Dianthus Therapeutics Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:DNTH
2026 Q2
6a6237b88379628c04d2479f TimesSquare U.S. Small Cap Growth 2Q26 Commentary
What the manager wrote
We have taken steps to increase our Biopharma exposure. One of the new positions we initiated this quarter is Dianthus Therapeutics, a clinical-stage biotechnology company developing novel complement-pathway antibodies for severe autoimmune and neuromuscular diseases, led by its lead candidate DNTH103.
News about NAS:DNTH
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers